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AbstrACt
Introduction North America is amid an opioid use 
epidemic. Opioid agonist treatment (OAT) effectively 
reduces extramedical opioid use and related harms. 
As with all pharmacological treatments, there are risks 
associated with OAT, including fatal overdose. There is 
a need to better understand risk for adverse outcomes 
during and after OAT, and for innovative approaches to 
identifying people at greatest risk of adverse outcomes. 
The Opioid Agonist Treatment and Safety study aims to 
address these questions so as to inform the expansion of 
OAT in the USA.
Methods and analysis This is a retrospective 
cohort study using linked, routinely collected health 
data for all people seeking OAT in New South Wales, 
Australia, between 2001 and 2017. Linked data include 
hospitalisation, emergency department presentation, 
mental health diagnoses, incarceration and mortality. 
We will use standard regression techniques to model 
the magnitude and risk factors for adverse outcomes 
(eg, mortality, unplanned hospitalisation and emergency 
department presentation, and unplanned treatment 
cessation) during and after OAT, and machine learning 
approaches to develop a risk-prediction model.
Ethics and dissemination This study has been approved 
by the Population and Health Services Research Ethics 
Committee (2018HRE0205). Results will be reported in 
accordance with the REporting of studies Conducted using 
Observational Routinely-collected health Data statement.
IntroduCtIon 
There have been dramatic increases in 
opioid-related morbidity and mortality across 
many high-income countries, including the 
USA, Canada and Australia,1–3 driven by 
increases in pharmaceutical opioid use,4–6 
and in North America, a rapid rise in the 
availability of illicit heroin and fentanyl.7 8 
In the USA, there are now over 100 opioid 
overdose deaths per day.1 Multiple HIV 
and hepatitis C outbreaks linked to opioid 
injection have occurred, often in rural areas, 
illustrating the reach of the crisis.9–13 The 
Council of Economic Advisers put the impact 
at US$504 billion in 2015, nearly 3% of gross 
domestic product.14 
As a chronic relapsing disease, access to 
effective treatment for opioid use disorders 
is a critical component of the response to the 
opioid epidemic.4 Opioid agonist treatment 
(OAT) is the most effective treatment for 
opioid use disorder,15 including prescription 
opioid use disorder.16 The main medications 
used for OAT are methadone, a full opioid 
agonist, and buprenorphine, a partial opioid 
agonist.
Risk of death from any cause is halved while 
on OAT compared with out-of-treatment opioid 
use disorder; risk of overdose death is reduced 
by 70%.17 Other harms from opioid use and 
injecting are also reduced while on OAT. HIV 
and hepatitis C acquisition are halved18 19 while 
on treatment. Health service use, particularly 
unplanned and crisis-driven hospitalisations 
and emergency department presentations, are 
strengths and limitations of this study
 ► The use of a population cohort of people with opioid 
use disorder, and people moving in and out of opioid 
agonist treatment with methadone and/or buprenor-
phine over an extended period (2001–2017).
 ► Linkage of disparate datasets addressing physical 
health, mental health and substance use, criminal 
justice and mortality.
 ► Cross-national funding and collaboration to inform 
responses to an epidemic.
 ► A key limitation is a lack of primary care data to bet-
ter quantify physical comorbidity.
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significantly reduced.20–22 Criminal offending and associ-
ated costs are significantly reduced.23–25
As with any pharmacological treatment, there are risks 
associated with OAT. Periods of elevated risk of fatal over-
dose are observed during treatment induction (the first 
4 weeks), particularly with methadone, and immediately 
following treatment cessation.26–28 Additional adverse 
outcomes during OAT may include non-fatal overdoses, 
accidents29 or cardiac problems resulting from QT 
interval prolongation.30 Adverse outcomes during OAT 
may also include events that are not directly related to 
treatment, but are still of importance due to their poten-
tial severity and impact on clinical care; for example, 
instances of self-harm and suicide. To date however, 
much of the postmarketing surveillance of methadone 
and buprenorphine has focused on diversion and illicit 
use of medications,31–33 with relatively less attention given 
to adverse outcomes of people in treatment or following 
treatment cessation. This is a significant knowledge gap 
that leaves OAT recipients at risk of harm.
Many questions in relation to adverse outcomes in OAT 
remain unanswered. Most importantly, it is not clear what 
patient, provider and treatment setting factors may influ-
ence mortality risk. There are also less severe, but likely 
more common, adverse outcomes in OAT that have 
largely been unexamined. For example, how common are 
non-fatal overdoses or other injuries during OAT induc-
tion? Are these outcomes more common among particular 
groups of people or in particular treatment settings? What 
other adverse outcomes occur after leaving treatment?
Identifying oAt recipients at highest risk of adverse outcomes
In the USA, OAT is offered in both clinic (where metha-
done and buprenorphine may be prescribed) and office-
based (buprenorphine prescribing only) settings which 
provide varying levels of monitoring and support. There 
are a variety of factors that play into matching patients 
with treatment setting, including the level of training 
of the provider (generalist vs specialist) and supportive 
resources (on-site vs off-site), and to date there are no 
evidence-based algorithms to guide care.
Information regarding substance use history, 
previous treatment, comorbidities, social supports and 
other factors that may influence treatment planning is 
obtained from people seeking OAT via clinical assess-
ment.34–36 However, individuals may be reluctant at an 
initial assessment to disclose details about the extent of 
their substance use and related issues, such as discon-
nection from family and criminal justice matters, or 
about mental illness and suicidality. Furthermore, there 
is no quantification of how much weight to give any 
specific issue, or combination of issues, in deciding on 
the most appropriate and safest treatment strategy for 
a specific individual. Although treatment guidelines 
emphasise the importance of identifying the appro-
priate treatment setting for people with risk factors 
for poorer outcomes,35 36 they do not consider more 
complex provider and setting factors, such as provider 
training, experience and caseload. Given the range 
of clinical, sociodemographic and treatment setting/
provider factors that are likely to affect risk in OAT, 
and the possibility that these factors may interact in 
currently unknown ways to magnify (or reduce) risk, 
self-reported histories alone are unlikely to provide 
sufficient detail to understand and predict individual 
risk.
Consistent with a move towards personalised medicine, 
there is a need for innovative approaches to identifying 
people at highest risk of adverse outcomes in OAT, that 
take into account medication-specific risks, the individu-
al’s history and provider factors, to produce an individ-
ualised probability of adverse outcome that can be used 
to guide treatment strategy. Machine learning offers such 
an approach. Machine learning is a flexible tool that 
allows for exploration of a much wider range of potential 
predictors and combinations of predictors than standard 
regression models. While standard regression models are 
focused on determining the direction and magnitude 
of risk conferred by specific factors, machine learning 
aims to maximise the predictive ability of a model. This 
approach has previously been used to identify Army 
veterans most at risk of suicide.37
There is considerable potential for machine learning 
to predict the probability of a specified adverse outcome 
in OAT through real-time application of an algorithm to 
routinely collected data. In practice, this will allow for 
the development of individualised treatment plans that 
take into account the individual’s specific probability of 
specific adverse outcomes, minimising risk and maxi-
mising treatment retention.
To address the need for greater knowledge of the 
frequency and magnitude of risk for adverse outcomes 
during and after OAT to support the expansion of OAT 
in the USA, the Opioid Agonist Treatment and Safety 
Study aims to:
1. Determine the magnitude of risk for specific adverse 
outcomes (eg, mortality, unplanned hospitalisation 
and emergency department presentation, and un-
planned treatment cessation) during and after OAT 
with methadone and buprenorphine.
2. Identify patient (sociodemographic characteristics, co-
morbidities), treatment (clinic or office-based setting, 
starting dose) and provider (training, caseload) fac-
tors associated with adverse outcomes during and after 
OAT with methadone and buprenorphine.
3. Develop risk-prediction models to identify patients 
at greatest risk of adverse outcomes during and after 
OAT.
MEthods And AnAlysIs
design
This is a retrospective cohort study using linked, 
routinely collected health and criminal justice data. 
The cohort includes all people seeking OAT in New 
South Wales (NSW), Australia, between 2001 (when 
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buprenorphine was approved for use for the treatment of 
opioid dependence in Australia) and 2017, with linkage 
to hospital admissions, emergency department presen-
tations, mental health diagnoses, incarceration episodes 
and mortality.
setting
Approximately 40% of Australia’s OAT recipients reside 
in NSW.38 Methadone and buprenorphine (including 
buprenorphine–naloxone) may be prescribed by physi-
cians or nurse practitioners. OAT is dispensed in a 
variety of settings including public and private clinics, 
community pharmacies and correctional facilities. In 
rural areas, local hospitals may also dispense OAT medi-
cines. All OAT is provided as daily supervised doses for 
the first 3 months of treatment. After 3 months, take-
home doses may be provided at the discretion of the 
prescribing doctor, with the number of take-home 
doses per week increasing with duration in treatment. 
The maximum recommended number of take-home 
methadone doses is four. OAT patients prescribed 
buprenorphine–naloxone may progress to a 28-day 
prescription of dispensed medicine if they have demon-
strated stability on a 2-week prescription over a number 
of months, but this rarely occurs in clinical practice. 
There are no charges for OAT recipients treated in 
public clinics or correctional facilities; OAT recipients 
who have their medication dispensed at private clinics 
or community pharmacies are charged daily dispensing 
fees (typically $A5–$A8 per day).39 40
datasets
The primary database for this linkage is the Electronic 
Reporting and Recording of Controlled Drugs (ERRCD) 
system. The ERRCD (formerly Pharmaceutical Drugs of 
Addiction System) contains records of all OAT prescribed 
in NSW, in any setting. People receiving OAT between 
2001 (when buprenorphine was first approved for use in 
OAT in NSW) and 2017 form the cohort for this study. 
Based on previous linkages, we estimate that the cohort 
will include at least 45 000 unique OAT recipients and 
over 600 000 person-years of observation.
As people seeking OAT must provide identification 
documents to obtain a prescription, personal identifiers 
in the ERRCD are considered reliable for probabilistic 
linkage to other routinely collected data. For this study, 
the ERRCD is probabilistically linked to five state-wide 
databases; linked variables are shown in table 1. The 
linkage process is managed by the Centre for Health 
Record Linkage in collaboration with data custodians, 
Table 1 Databases linked in the Opioid Agonist Treatment and Safety Study
Database name Database description Linked variables*
Electronic Reporting and 
Recording of Controlled 
Drugs
Authorisation for dispensing methadone or 
buprenorphine for the treatment of opioid 
dependence.
Dates of OAT entry and cessation.
Primary opioid of concern.
Start and final dose.
Prescriber identification number.
Dosing point.
Date of provider accreditation.
Date of provider’s first OAT authority.
Statistical area of OAT recipient’s address.
Statistical area of OAT provider’s practice.
Reason for OAT cessation.
Admitted Patients Data 
Collection
All hospitalisations in all public, private, 
psychiatric and repatriation hospitals in 
NSW.
Dates of admission and separation.
Planned or unplanned admission.
Diagnoses (underlying and contributing).
Procedures.
Mode of separation.
Emergency Department 
Data Collection
Presentations to emergency departments in 
NSW.
Date of presentation and separation.
Triage category.
Diagnosis (underlying only).
Planned or unplanned presentation.
Mode of separation.
Mental Health Ambulatory 
Data Collection
Mental healthcare for non-admitted patients, 
including day programmes, psychiatric 
outpatients and outreach services.
Mental health diagnoses (primary and additional).
Re-offending Database Court appearances, juvenile detention and 
adult incarceration in NSW.
Dates of prison reception and release.
Level of Service Inventory-Revised risk category.
Registry of Births, Deaths 
and Marriages and Cause of 
Death Unit Record File
Deaths registered in NSW. Date of death.
Cause of death (underlying and contributing).
*All linked databases include sex, month and year of birth, and Indigenous status.
NSW, New South Wales; OAT, opioid agonist treatment. 
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using best practice privacy-preserving protocols.41 
Researchers do not receive identifying data for any indi-
vidual in the cohort at any time.
outcomes
Adverse outcomes that will be assessed as outcomes are 
all-cause, drug-induced, suicide and injury deaths, as well 
as unplanned hospitalisations and emergency department 
presentations related to each of these categories. Interna-
tional Classification of Diseases 10th Revision codes for 
defining these outcomes are shown in table 2. Outcomes 
will be measured during four distinct time periods during 
and out of OAT (treatment-by-time periods):
Induction: the first 28 days of a new episode of OAT.
Remainder of time in OAT: the 29th day of OAT on-
wards, until the end date of the treatment episode or 
end of follow-up.
Immediately post-OAT: the first 28 days after the end 
of a treatment episode.
Remainder of time out of OAT: the 29thh day follow-
ing OAT cessation onwards, until the first day of a new 
treatment episode, or end of follow-up.
statistical analysis plan
To address aims 1 and 2 (determining the magnitude and 
risk factors for adverse outcomes during and after OAT), 
we will allocate all adverse outcomes to the specified treat-
ment-by-time periods. We will calculate rates of adverse 
outcomes using standard methods and 95% Poisson CIs. 
Poisson regression will be used to calculate adjusted inci-
dence rate ratios for specific adverse outcomes, comparing 
rates during/after methadone to the same time periods 
for buprenorphine. Should concerns arise regarding 
confounding by indication, we will explore methods such 
as propensity score matching and instrumental variables 
(assuming we can identify a reliable indicator of the prob-
ability of a clinician prescribing buprenorphine). In these 
analyses, special attention will be given to testing whether 
patients who transfer from buprenorphine to methadone 
during a treatment episode are at increased risk of death 
during and after OAT, and whether unplanned treatment 
cessation is reduced, compared with patients who remain 
on buprenorphine.
We will use survival analysis methods to identify 
risk factors—including patient, setting and provider 
factors—for adverse outcomes during specific 
treatment-by-timetime periods. Each adverse outcome 
specified above will be considered separately. We will 
investigate the effect of repeated/interrupted treatment 
exposure by using methods that incorporate multiple 
observations per person (eg, frailty models; generalised 
linear mixed models or generalised estimating equa-
tions). Risk factors will be incorporated into multivari-
able models on the basis of results of univariate analyses. 
Risk factors will be separately identified for methadone 
and buprenorphine, during specific treatment-by-time 
periods. As exact dates of incarceration are included in 
the linked dataset, we will account for time in custody 
as a time-dependent covariate, and examine how risk of 
adverse outcomes varies by incarceration status.
Aim 3 is to develop risk-prediction models to identify 
patients at greatest risk of adverse outcomes during and 
after OAT. We will use two main approaches to machine 
learning to develop our risk-prediction models: tree-
based methods and methods based on logistic regres-
sion. Classification trees identify individuals at increased 
risk of adverse outcomes by stratifying or segmenting 
the population into groups that maximise the predictive 
accuracy. This approach differs from conventional regres-
sion analysis in that no assumptions are required as to 
the nature of the relationship between the predictors 
and outcomes. In particular, it does not assume linearity 
or additivity of predictor variables. We will use random 
forests, a machine-learning method, for classification42 
that generates many classification trees and ranks their 
predictive importance. Each tree is based on a separate 
bootstrapped pseudo-sample of the original dataset which 
protects against over-fitting.42
Logistic penalised regression models will be devel-
oped.43 This approach ‘penalises’ what one would 
consider less realistic values of the unknown model 
parameters, reducing instability caused by high correla-
tions among predictors. Three penalties will be evaluated: 
the ridge penalty, the lasso penalty and an intermediate 
mixing parameter penalty. The ridge penalty uses propor-
tional coefficient shrinkage to retain all predictors. The 
lasso penalty favours sparse models that force coefficients 
for all but one predictor in each strongly correlated set to 
zero. The intermediate elastic net penalty combines both 
approaches.44
We will compare the candidate models from each tech-
nique and create additional model ensembles which 
combine prediction outcomes across candidate models 
and can produce superior models. Models will be trained 
using k-fold cross-validation and the champion model 
will be selected based on a comparison of the area under 
the curve of the original algorithms and the ensemble 
models.
Patient and public involvement
There was no patient or public involvement in the devel-
opment of the study design. A Community Reference 
Panel was consulted as part of the process of gaining 
ethical approval for the study; this involved consultations 
Table 2 Defining ICD-10 codes for adverse outcomes 
during and after OAT
Outcome ICD-10 codes
Drug-induced F11-F16, F19, F55, X40-X44, X60-X64, 
X85, Y10-Y14
Suicide/self-harm X60-X84, Y87.0
Injury V01-X59
ICD-10, International Classification of Diseases 10th Revision; OAT, 
opioid agonist treatment.
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with people who inject drugs and people with experience 
of OAT, including representation of Aboriginal people 
with OAT experience. These consultations provided 
information to inform our approach to disseminating 
findings of this project. We will prepare one-page summa-
ries of key findings for distribution to OAT clinics, other 
drug treatment services and harm-reduction services.
EthICs And dIssEMInAtIon
data storage, retention and access
To protect privacy and confidentiality, approval for the 
linkage of health data in NSW is provided under strict 
conditions for the storage, retention and use of the data. 
The current approval permits storage of the data at one 
site, the University of New South Wales, for up to 7 years 
following the date of publication of results. Researchers 
wishing to undertake additional analyses of the data are 
invited to contact the corresponding author to discuss 
requirements, including the need to obtain approval 
from the Population and Health Services Research Ethics 
Committee for data access. Data may only be supplied for 
analysis within Australia.
dissemination
A key audience for dissemination will be US-based addic-
tion medicine and addiction psychiatry physicians and 
policy stakeholders. Project findings will be disseminated 
at scientific conferences and in peer-reviewed journals, 
with policy briefs distributed via a website. Outputs will 
include publications examining the magnitude of and risk 
factors for adverse outcomes during and after OAT, the 
development and performance of the machine-learning 
model, and methodological papers. As the study uses 
routinely collected health data, findings will be reported 
in accordance with the REporting of studies Conducted 
using Observational Routinely-collected health Data 
statement.45
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